Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet

Diabetes, Obesity and Metabolism

Volumn 18, Issue 7, 2016, Pages 702-706

  Nishimura, R ^a   Omiya, H ^b   Sugio, K ^b   Ubukata, M ^b   Sakai, S ^b   Samukawa, Y ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

continuous glucose monitoring (CGM); glycaemic control; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; KETONE; LUSEOGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; SORBITOL;

ADULT; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); LETTER; LOW CARBOHYDRATE DIET; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; HYPOGLYCEMIA; METABOLISM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIET, CARBOHYDRATE-RESTRICTED; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; TREATMENT OUTCOME;

EID: 84954286373     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12611     Document Type: Letter

References (11)

1. Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs 2014; 74: 945–950.
2. Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014; 15: 2741–2749.
3. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245–1255.
4. Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin 2014; 30: 1219–1230.
5. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin 2014; 30: 1231–1244.
6. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136–142.
7. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14: 5–14.
8. Nishimura R, Osonoi T, Kanada S et al. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-hour glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab 2015; 17: 800–804.
9. Seino Y, Nanjo K, Tajima N et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. J Diabetes Investig 2010; 1: 212–228.
10. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metabol 2015; 100: 2849–2852.
11. Hayami T, Kato Y, Kamiya H et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 2015; 6: 587–590.